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Background:MOV10 inhibits HIV-1 replication after being packaged.
Results: A Gag binding plus all but one of seven helicase domains are required for MOV10 packaging. Nearly all residues are
required for anti-HIV-1 activity.
Conclusion:Gag binding is not sufficient forMOV10packaging, andmultiple discontinuous domains regulateMOV10 activity.
Significance: These findings uncover a new packaging mechanism and provide new insights into MOV10 antiviral activity.
Discovery of novel antiretroviral mechanism is essential for
the design of innovative antiretroviral therapy. Recently, we and
others reported that ectopic expression of Moloney leukemia
virus 10 (MOV10) protein strongly inhibits retrovirus replica-
tion. MOV10, a putative RNA helicase, can be packaged into
HIV-1 virions by binding to the nucleocapsid (NC) region ofGag
and inhibit viral replication at a postentry step. Here, we report
critical determinants forMOV10 virion packaging and antiviral
activity. MOV10 has 1,003 amino acids and seven helicase
motifs. We found that MOV10 packaging requires the NC basic
linker, and Gag binds to the N-terminal amino acids 261–305
region of MOV10. Our predicted MOV10 three-dimensional
structuremodel indicates that the Gag binding region is located
in a structurally exposed domain, which spans amino acids
93–305 and is Cys-His-rich. Simultaneous mutation of residues
Cys-188, Cys-195,His-199,His-201, andHis-202 in this domain
significantly compromised MOV10 anti-HIV-1 activity. Nota-
bly, although MOV10-Gag interaction is required, it is not suf-
ficient forMOV10packaging,which also requires itsC-terminal
all but one of seven helicase motifs. Moreover, we have mapped
the minimal MOV10 antiviral region to amino acids 99–949,
indicating that nearly all MOV10 residues are required for its
antiviral activity. Mutations of residues Cys-947, Pro-948, and
Phe-949 at the C terminus of this region completely disrupted
MOV10 anti-HIV-1 activity. Taken together, we have identified
two critical MOV10 packaging determinants and eight other
critical residues for anti-HIV-1 activity. These results provide a
molecular basis for further understanding the MOV10 antiret-
roviral mechanism.
Moloney leukemia virus 10 homolog (MOV10)2 was origi-
nally discovered frommice as a GTP-binding protein (1). Later,
it was found that MOV10 has seven highly conserved helicase
motifs in the C-terminal region, and MOV10 was then pro-
posed as a putative superfamily-1 (SF-1) RNAhelicase (2). Heli-
cases separate duplex DNA and/or RNA into single strands in
an ATP-dependent reaction. They may have up to seven heli-
case motifs (I, Ia, II, III, IV, V, and IV) and are classified into
three superfamilies (SF-1, SF-2, SF-3) and two small families
(F-4, F-5) (3). The physiological function of MOV10 is still
unclear, but MOV10 was found in the RNA-induced silencing
complex (4) as well as in the mRNA processing (P) bodies and
stress granules (5), indicating that MOV10 may play an impor-
tant role in RNA biology and metabolism. Recently, we and
others reported that ectopic expression of MOV10 inhibits a
wide range of retrovirus replication, including HIV-1, simian
immunodeficiency virus, murine leukemia virus, and equine
infectious anemia virus (6–8). Notably, MOV10 has multiple
antiviral activities. It not only inhibits viral infectivity (6–8),
but also reduces viral production, blocks Gag proteolytic proc-
essing, and lowers Gag protein stability (6). To inhibit viral
infectivity, MOV10 is packaged into HIV-1 virions from pro-
ducer cells via an interactionwith the nucleocapsid (NC) region
of Gag in an RNA-dependent manner (8). After that, it blocks
viral reverse transcription directly or indirectly in the target
cells, resulting in 20–100-fold reduction of viral infectivity.
Thus, MOV10 has very broad and potent antiretroviral activi-
ties, and understanding this novel antiretroviral mechanism
will provide new strategies for developing more effective anti-
retroviral therapies.
Here, we studied the mechanism of MOV10 packaging into
HIV-1 virions, which is an essential step for inhibition of viral
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infectivity. Using a combination of deletion, mutation, and
homology modeling techniques, we have identified two critical
domains that determine its packaging. In addition, we also
identified several other residues that are critical for antiviral
activity. These results provide new insights into the as yet
poorly defined MOV10 antiretroviral mechanism.
EXPERIMENTAL PROCEDURES
Plasmids—pNL-Lucenv, pcDNA3.1-MOV10-V5-His6, and
pcDNA3.1-A3G-V5-His6 were described before (8, 9). The
Gag-CFP fusion constructs expressing MA-CFP, Gag377-
CFP, Gag384-CFP, Gag391-CFP, Gag405-CFP, Gag411-
CFP, Gag426-CFP, Gag432-CFP, and full-length Gag-CFP
were obtained from the Spearman laboratory (10, 11). These
Gag genes were derived from a codon-optimized HXB2 Gag
sequence (14). Previously, we also cloned thisGag gene into the
pcDNA3.1 vector to express a C-terminally GST-V5-tagged
Gag protein (8). The pcDNA3.1-Gag-HA-FLAG expression
vector was created from this pcDNA3.1-Gag-GST-V5-His6
vector by replacing the GST tag with a HA-FLAG linker after
NotI/XbaI digestion. To express MOV10 deletion mutants,
partially deletedMOV10 geneswere amplified by PCR and then
cloned into the pcDNA3.1-V5-His6 vector using the pcDNA3.1
Directional TOPO® Expression kit (Invitrogen). Other MOV10
mutations were created directly in the pcDNA3.1-
MOV10-V5-His6 vector using the QuikChange XL site-di-
rected mutagenesis kit (Stratagene). All of these constructs
were verified by DNA sequencing.
MOV10 Virion Incorporation Assay—HIV-1 particles and
virus-like particles (VLPs) containing MOV10 were produced
similarly from 293T cells cultured in 6-well plates by transfect-
ing them with a 3-g HIV-1 proviral construct pNL-Lucenv
and 3-g MOV10 expression vector, or 3-g Gag-CFP fusion
construct and 3-g MOV10 expression vector, respectively.
Supernatants were harvested 48 h after transfection and clari-
fied by 12,000 rpmcentrifugation for 2min at 4 °C.Virionswere
further purified by spinning the clarified supernatants through
a 20% sucrose cushion at 296,000  g for 30 min at 4 °C using
the S100AT6 rotor (Sorvall). Viral pellets were resuspended in
phosphate-buffered saline (PBS) and analyzed by Western
blotting.
Determination of MOV10 and Gag Interaction by Anti-HA
Immunoprecipitation—293T cells cultured in 6-well plates
were transfected with a 3-g MOV10 expression vector and
3-g codon-optimizedGag-HA-FLAG expression vector. Cells
were then lysed with a buffer containing 50 mM Tris-HCl, pH
7.6, 100 mM NaCl, 1% Triton X-100, and 5 mM EDTA. The
cytosolic fractions were collected and incubated with anti-HA-
agarose beads (Sigma) for 3 h at 4 °C. Beadswere then loaded on
Micro Bio-Spin chromatography columns (catalogue 732-
6204; Bio-Rad) and washed extensively with Tris-buffered
saline containing 25 mM Tris-HCl, pH 7.2, and 150 mM NaCl.
After that, beads were boiled in sample loading buffer contain-
ing 60mMTris-HCl, pH 6.8, 7.8% glycerol, 2% SDS, 1.55% dithi-
othreitol, and 0.001% bromphenol blue, and bead-associated
proteins were analyzed by Western blotting.
MOV10 Anti-HIV-1 Activity Assay—Viruses were produced
from 293T cells cultured in 6-well plate by transfecting them
with a 3-g MOV10 expression vector, 3-g pNL-Lucenv,
and 0.3-g VSV-G expression vector. Viral production was
measured by the p24Gag capture enzyme-linked immunosor-
bent assay (ELISA). Virions equivalent to5 ng of p24Gag were
used to infect 3 105 CEM-SS cells in a 48-well plate by spin-
oculation at 1,200 g, 25 °C, for 2 h.Cellswere cultured for 36 h
and were lysed in a buffer (25 mM Tris-HCl, pH 7.8, 2 mM
dithiothreitol, 2 mM 1,2-diaminocyclohexane-N,N,N’,N’-tet-
raacetic acid, 10% glycerol, 1% Triton X-100). After removing
the nuclei, the cytosolic fraction was used to determine the
luciferase activity with a luciferase assay kit (Promega).
Western Blotting—Horseradish peroxidase (HRP)-conju-
gated anti-HA antibody (Roche Applied Science) or HRP-con-
jugated anti-V5 antibody (Invitrogen) was used to directly
detect Gag, APOBEC3G (A3G), and MOV10 proteins that
express HA or V5 tag. The rabbit anti-human MOV10 poly-
clonal antibody was from Proteintech Group. The mouse anti-
GFP monoclonal antibody and goat anti-actin polyclonal anti-
body (C-11) were from Santa Cruz Biotechnology. The mouse
anti-HIV-1 Gag monoclonal antibody (183-H12-5C) was from
the National Institutes of Health AIDS Research and Reference
Reagent Program. HRP-conjugated anti-mouse, rabbit, and
goat immunoglobulin G secondary antibodies were from
Pierce. Detection of the HRP-conjugated antibody was per-
formed using an enhanced chemiluminescence detection kit
(Amersham Biosciences).
Homology Modeling of MOV10 Protein Structure—The
MOV10 protein three-dimensional structure was modeled
using Discovery Studio Client 2.5 (Accelrys Software, San
Diego, CA). The template for sequence-based homology mod-
eling is fromhuman nonsense-mediated decay factor up frame-
shift 1 (UPF1) (ProteinData Bank code 2WJY) (12). Fivemodels
were generated and evaluated. The final model was selected
after energy minimization. The energy calculations were all
based on CHARMm (Chemistry at Harvard Macromolecular
Mechanics). The parameters for sequence alignment, build
homology, and energy minimization were basically setup as
default.
RESULTS
Packaging of MOV10 into HIV-1 Virions from Human CD4
T Cells—Virion packaging is an essential and critical step for
MOV10 to inhibit HIV-1 infectivity. Our previous demonstra-
tion of MOV10 virion packaging was done in an overexpressed
condition (8). It is important to knowwhetherMOV10 is incor-
porated into HIV-1 virions during normal replication in CD4
T cells. To address this issue, we infected human CD4 T cell
lines H9, CEM-SS, and CEM-T4withHIV-1. After detection of
productiveHIV-1 replication,HIV-1 virionswere purified from
the culture medium by ultracentrifugation, and proteins were
analyzed by Western blotting. It was found that HIV-1 virions
were specifically detected from the supernatant of infected
cells, and importantly,MOV10was detected from these virions
(Fig. 1, lanes 4-6, lower panels). This result is consistentwith the
previous finding by Chertova et al. that MOV10 is packaged
into HIV-1 virions from monocyte-derived macrophages (13).
It was also found that MOV10 expression was significantly
reduced in HIV-infected cells (Fig. 1, upper panels), which sup-
MOV10 Anti-HIV-1 Domains
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ports our previous conclusion thatHIV-1 can suppressMOV10
expression (8). Thus, MOV10 is packaged into HIV-1 virions
during natural HIV-1 infection.
Requirement ofHIV-1NCBasic Linker forMOV10Packaging—
Although we demonstrated that MOV10 interacts with NC for
packaging (8), the precise binding domain is still unclear. To
map the minimal NC region, we utilized a panel of previously
described Gag-CFP fusion constructs that express matrix
(MA), capsid (CA), spacer peptide 1 (SP1), and different NC
regions of Gag (10, 11). The Gag gene in these constructs was
derived from the codon-optimized version of HXB2 Gag
sequence (14), so their expression is Rev-independent.
HIV-1 NC consists of a N-terminal interaction (I) domain,
followed by two zinc fingers, which are separated by a basic
linker (Fig. 2A). SevenNC deletion constructs that span theNC
region were selected for mapping: the Gag377-CFP expresses
MA, CA, and SP1; the Gag384-, Gag391-, Gag405-, Gag411-,
and Gag426-CFP additionally express the N-terminal NC
region up to theminimal I domain, the entire I domain, the first
zinc finger, the basic linker, or the second zinc finger, respec-
tively; and the Gag432-CFP expresses the full-length NC (Fig.
2A). Two other constructs, MA-CFP, which only expresses
MA, and Gag-CFP, which expresses the full-length Gag, were
used as controls. All these constructs except for MA-CFP and
Gag377-CFPwere shown to produce VLPswith normal density
(10, 11), and they were used successfully to demonstrate that
A3G packaging requires the NC basic linker (10).
We then transfected each of these constructs with aMOV10
or A3G expression vector into 293T cells and purified VLPs
from the supernatants by ultracentrifugation. It was found that
A3G, MOV10, and all CFP fusion proteins were expressed at
similar levels in cells. In addition, all these CFP fusion proteins
except for the Gag377-CFP andMA-CFP were able to produce
VLPs (Fig. 2B), which is consistent with previous reports (10,
11). Nonetheless, A3G and MOV10 proteins were only
detected in VLPs produced from the Gag411-, Gag426-,
Gag432-, and full-length Gag-CFP fusion constructs (Fig. 2B,
lanes 5–7, 9, 14–16, and 18). These results indicate that like the
A3G protein, MOV10 also requires the NC basic linker for
virion packaging.
N-terminal AA 261–305 Region of MOV10 Interacts with
HIV-1 Gag—Next, we studied which domain of MOV10 inter-
acts with HIV-1 Gag. MOV10 has 1,003 AA and seven C-ter-
minal helicase motifs (I, Ia, II, III, IV, V, and VI) (Fig. 3A). Ini-
tially, we created 12 MOV10 N-terminal and C-terminal
deletionmutants (Fig. 3B, lanes 2–13). After that, the wild-type
(WT) or mutant MOV10 proteins were expressed with codon-
optimized HIV-1 HXB2 Gag that has a C-terminal HA-FLAG
tag in 293T cells, andMOV10-Gag interaction was determined
by immunoprecipitation with anti-HA antibodies.
It was found that all these MOV10 proteins except for two
mutants 431–1003 and 1–911 were well expressed (Fig. 3B,
lanes 2–13). Among these well expressed MOV10 proteins,
only two mutants 306–1003 and 507–1003 were not pulled
down by Gag (Fig. 3B, lanes 3 and 5). Because Gag could pull
down mutant 93–1003 but not mutant 306–1003, and all the
other MOV10 mutants that were pulled down by Gag express
the AA 93–305 region, we concluded that the AA 93–305
region is required for MOV10-Gag interaction. Next, we cre-
ated another 12MOV10mutants bearing a series ofN-terminal
deletion in the AA 93–305 region tomap the exact Gag binding
domain (Fig. 3B, lanes 15–22 and 27-30). It was found that
mutants bearing N-terminal deletions up to the AA 251 posi-
tion were all efficiently pulled down by Gag (Fig. 3B, lanes
15–22). However, mutant 261–1003 was pulled down at rela-
tively lower efficiency, and this efficiency formutants 281–1003
and 291–1003 was further reduced (Fig. 3B, lanes 28–30). We
then created another mutant 271–1003, but this mutant was
not expressed (data not shown). Thus, we concluded that the
AA 261–305 region is required for MOV10 interaction with
Gag.
Gag Binding Domain of MOV10 Is Required but Not Suffi-
cient for Virion Packaging—Having mapped the Gag binding
domain, we determined how it contributes to virion packaging.
MOV10 mutants were expressed with a HIV-1 proviral con-
struct in 293T cells, and virions were purified from culture
supernatant by ultracentrifugation. After that, virion-associ-
ated proteins were detected by Western blotting.
When those MOV10 N-terminal deletion mutants were
compared (Fig. 4, lanes 2–5 and 15–27), we found that those
mutants interacting with Gag were all packaged into virions
(Fig. 4, lanes 2 and 15–25), and mutants 281–1003, 291–1003,
306–1003, 431–1003, and 507–1003, which did not interact
with Gag, were all poorly packaged (Fig. 4, lanes 3–5, 26, and
27). These results indicated that Gag binding is required for
MOV10 virion packaging.
FIGURE 1. MOV10 is packaged into HIV-1 virions from human CD4 T
cells. 3 105 H9, CEM-SS, or CEM-T4 cells were infectedwith NL HIV-1 equiv-
alent to 20ngof p24Gag, respectively. Six days later, virionswerepurified from
the culture supernatants by ultracentrifugation through a 20% sucrose cush-
ion. Cells and virions were lysed, and proteins were analyzed by Western
blotting. MOV10 and A3Gwere detected by anti-V5 antibodies, and Gag-CFP
fusions were detected by anti-GFP antibodies.
MOV10 Anti-HIV-1 Domains
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Next, we compared MOV10 C-terminal deletion mutants
(Fig. 4, lanes 6–13 and 29–35). It was found that mutants
1–312, 1–430, 1–506, 1–949, 1–952, and 1–955 were detected
in the virions (Fig. 4, lanes 6–8, 13, and 33–35).Mutants 1–926,
1–943, and 1–946 were also detected at relatively lower effi-
ciency, but this was due to their lower expression levels in cells
(Fig. 4, lanes 30–32). Thus, all of these mutants are packaged
into the virions, which is consistent with that they all have an
FIGURE 2. MOV10 packaging into HIV-1 requires the NC basic linker. A, schematic illustrates p55Gag and NC for creating Gag-CFP fusion constructs. The
number indicates the C-terminal AA residue expressed, with the first Gag residue considered 1. B, MOV10 or A3Gwas expressedwith indicated Gag-CFP fusion
proteins in 293T cells. Virionswere purified through a 20% sucrose cushion via ultracentrifugation. Cellular and virion-associated proteinswere determined by
Western blotting with the indicated antibodies.
FIGURE 3. HIV-1 Gag binds to the N-terminal AA 261–305 region of MOV10. A, schematic illustrates MOV10 N-terminal or C-terminal deletion mutations.
Numbers indicate AA positions. The locations of the putative CH domain (see Fig. 6) and seven helicase motifs are indicated. The border of the putative CH
domain, the first residue of the helicase motif I, and the last residue of the helicase motif VI are numbered. B, Gag binding domain of MOV10 was mapped by
immunoprecipitation (IP). The indicated MOV10 deletion mutants were expressed with HA-tagged codon-optimized HIV-1 HXB2 Gag in 293T cells. Proteins
were pulled down by anti-HA antibody and analyzed by Western blotting.
MOV10 Anti-HIV-1 Domains
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intact Gag binding domain. Nonetheless, we found that four
mutants 1–592, 1–662, 1–781, and 1–911 were not packaged
(Fig. 4, lanes 9–12), although they still bound to Gag (Fig. 3B).
This result indicated that Gag binding might not be sufficient,
and there may be additional determinant(s) in the C-terminal
region for MOV10 packaging.
Helicase Domain Is Required for MOV10 Virion Packaging—
To search for additional packaging determinant(s), we com-
pared those four C-terminal deletion mutants that were not
packaged. We noticed that they lost at least one helicase motif,
as indicated in Fig. 3A. We wondered whether these helicase
motifs could play a role in virion incorporation. Previously, we
created seven helicase motif mutants: Mut I, Mut Ia, Mut II,
Mut III, Mut IV, Mut V, and Mut VI, which have alanine sub-
stitution(s) of the critical residues in the corresponding helicase
motifs (8).
When their anti-HIV-1 activity was determined, it was found
that all of these mutants except for Mut V significantly lost
anti-HIV-1 activity (Fig. 5A, upper panel), which is consistent
with our previous observation (8). We then determined their
ability for virion incorporation as well as interactions with Gag.
It was found that only Mut V was detected in HIV-1 virions,
whereas Mut I, Mut Ia, Mut II, Mut III, Mut IV, and Mut VI
were not, although they were expressed at similar levels in cells
(Fig. 5A, lower panels). In addition, unlike the mutant 306–
1003 that lacks the Gag binding domain, all of these mutants
were still able to interact with HIV-1 Gag (Fig. 5B). These
results indicated that although the seven helicasemotifs are not
required for MOV10-Gag interaction, all but one of them are
required for MOV10 packaging.
MOV10 Three-dimensional Structure Model—To under-
stand why the MOV10 N-terminal region is so critical for Gag
interaction and virion packaging, we predicted the MOV10
three-dimensional structure by homology modeling. MOV10
shares 40% AA sequence homology with another SF-1 RNA
helicase, the UPF1 protein (supplemental Fig. S1). Based on the
known UPF1 three-dimensional structure (12), we created a
MOV10 structure model. In this model, MOV10 shows a RNA
helicase core domain possessing seven conserved helicase
motifs (Fig. 6A). Similar to UPF1, MOV10 also shows a struc-
turally exposed N-terminal region. Interestingly, UPF1 has a
Cys-His-rich (CH) domain in this region, functioning as a zinc
finger that binds to three zinc atoms. Similarly, MOV10 has
four cysteines and nine histidines in theAA 93–260 region (Fig.
6, A and B), which is immediately followed by the Gag binding
domain from AA 261 to 305. Our model predicts that the AA
261–305 region has two -helices separated by a coiled coil
(Fig. 6A). It is possible that the entire AA 93–305 region con-
sists of a putative CH domain, which explains why it is so
important for Gag binding and virion packaging.
To dissect the function of this domain further, we mutated
His-167, Cys-172, Cys-188, Cys-195, His-199, His-201, and
Cys-202 by introducing single-point and multiple-point muta-
tions (Fig. 6C). After that, their anti-HIV-1 activity was meas-
ured as before. It was found that the H167R, H167L, C172S,
C188S, C195S, H199R, H199L, H201L, and C202S single-point
mutations as well as the H199L/H201L (HH2L) and H201A/
C202S (HCAS) double-point mutations could not disrupt
MOV10 anti-HIV activity; however, the C188A/C195A/
H199A/H201A/C202A (CCHHC5A) quintuple-point muta-
tion significantly disrupted MOV10 anti-HIV-1 activity (Fig.
6C). This result indicated that residues Cys-188, Cys-195, His-
199, His-201, and Cys-202 are involved in MOV10 antiviral
activity, and they may be able to compensate each other to
support this MOV10 activity.
Identification of Other MOV10 Antiviral Regions—Having
determined Gag binding and virion packaging, we next directly
measured the anti-HIV-1 activity of these N- or C-terminal
deletionmutants ofMOV10. It was found that theWT protein,
three N-terminal deletion mutants 93–1003, 96–1003, and
FIGURE4.GagbindingdomainofMOV10 isnot sufficient forvirionpackaging.The indicatedMOV10mutantswereexpressedwithHIV-1proviral construct
in 293T cells. Virions were purified, and virion incorporation of these mutants was determined by Western blotting.
MOV10 Anti-HIV-1 Domains
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FIGURE 5. All but one of seven helicase motifs are also required for MOV10 virion packaging. A, anti-HIV-1 activity and virion incorporation of
MOV10 helicase mutants. The indicated MOV10 mutants were expressed with VSV-G pseudotyped pNL-Luc reporter viruses in 293T cells, and
viral infectivity was analyzed in CEM-SS cells. Viral infectivity is presented as relative value, with the infectivity of viruses produced in the presence of a
control vector as 100%. The S.E. were calculated from three independent experiments. In addition, virions were purified by ultracentrifugation, and
cellular and virion proteins were analyzed by Western blotting. B, interaction of MOV10 helicase mutants with HIV-1 Gag, as determined by the same as
in Fig. 3B.
FIGURE 6.MOV10 three-dimensional structure model. A, ribbon structuremodel of human MOV10 protein from AA 122 to 968. It was generated from the
x-ray structure of humanUPF1 protein fromAA 116 to 914 (Protein Data Bank code 2WJY). The C-terminal core structure of RNA helicase domain from residue
306 to 968 is shown in blue; the Gag binding domain from residue 261 to 305 is shown in light blue; and the N-terminal part of a potential CH-domain from
residue 122 to 260 is shown inmagenta. In this CH domain, histidines are shown in green, cysteines are shown in orange, and their position is indicated by the
corresponding number. B, protein sequence of MOV10 from AA 93 to 305. Histidines are shown in green, cysteines are shown in orange, and the Gag binding
sequence from AA 261 to 305 is underlined. Residues that were targeted for mutagenesis are also underlined. C, anti-HIV-1 activity of MOV10 CH domain
mutants, as determined in Fig. 5A. Their cellular expression was determined by Western blotting.
MOV10 Anti-HIV-1 Domains
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99–1003, and three C-terminal deletion mutants 1–949,
1–952, and 1–955 had similar levels of anti-HIV-1 activities,
which reduced viral infectivity by 100-fold; and all the other
mutants almost completely failed to reduce viral infectivity (Fig.
7A). Thus, MOV10 mutants that were not packaged into viri-
ons all lost antiviral activity, and several mutants that were
packaged into virions also lost antiviral activity. These results
indicate that after being packaged into virions, MOV10 needs
additional domains to inhibit viral replication. Because the
99–1003 and 1–949 mutants were active whereas the 101–
1003 and 1–946 mutants were inactive, the AA 99–949 region
might be essential for MOV10 anti-HIV-1 activity.
To test this possibility, we created another MOV10 mutant
that only expresses the AA 99–949 region and measured its
activity. It was found that mutant 99–949 had almost the same
levels of anti-HIV activity as the WT proteins (Fig. 7B, top
panel). Next, we created two other mutants: the 99–100
mutant, which has a deletion of residues 99 and 100, and the
947–949 mutant, which has a deletion of residues 947, 948,
and 949.All of these residues are located in the border of theAA
99–949 region. It was found that the 99–100mutant was still
active, whereas the 947–949 mutant completely lost antiviral
activity (Fig. 7B, top panel). We then determined the virion
packaging of mutants99–100,947–949, and 99–949, and it
was found that all of these mutants were efficiently packaged
into virions (Fig. 7B, lower panels). Thus, residues 99–949 com-
pose the minimal MOV10 antiviral region, whereas residues
947, 948, and 949 are also critical for MOV10 antiviral activity.
DISCUSSION
In this report, we studied MOV10 antiretroviral activity by
mapping its critical antiviral domains and residues. We first
studied the MOV10 packaging mechanism because virion
packaging is a critical step for its antiviral activity. Previously,
we reported that MOV10 is packaged into HIV-1 virions via an
interaction with NC in an RNA-dependent manner (8). It has
been reported that A3G also interacts with HIV-1 NC in a sim-
ilar manner and gets packaged into HIV-1 virions (8, 15–19)
and that the basic linker of NC is required for A3G packaging
(10). Using the same system, we found that the NC basic linker
is also required forMOV10 packaging (Fig. 2B). Thus, A3G and
MOV10 share a very similar packaging mechanism. This simi-
larity raises a question ofwhether they competewith each other
for virion packaging during naturalHIV-1 infection, whichmay
compromise their anti-HIV-1 activity. However, it should be
noted that Vif potently inhibits the encapsidation of A3G by
HIV-1 (20–24), which should completely disrupt this competi-
tion. On the other hand, it has been reported that A3G binds to
MOV10 (25–27). Thus, evenwhen the neutralization ofA3Gby
Vif is incomplete, remnant A3Gproteinsmay enhanceMOV10
packaging as long as the domain on A3G that binds to MOV10
does not overlap with the domain that binds to NC.
We have mapped the Gag binding domain of MOV10 to the
N-terminal AA 261–305 region (Fig. 3B). Interestingly, this
region is located in a putative CH domain, which spans the AA
93–305 region (Fig. 6A). The CH domain was recently recog-
nized as a novel class of protein-protein interaction module
(28). Indeed, the UPF1 CH domain binds to UPF2 (29). Thus, it
is not coincidental that Gag binds to this domain of MOV10.
Nonetheless, we found that Gag binding is not sufficient for
MOV10 packaging. A similar observation was made in the
study of A3G virion packaging by Huthoff and Malim (30).
They found that when the packaging motif 124YYFW127 was
mutated, A3G became resistant to virion packaging, but it still
interacted with HIV-1 Gag in an RNA-dependent manner. In
addition, TSG101 also interact with HIV-1 Gag (31), but it is
poorly packaged into HIV-1 virions. Thus, Gag binding is not
the sole requirement for virion packaging. Indeed, we found
that in addition to the Gag binding domain, MOV10 helicase
motifs play an important role in its virion packaging. Our anal-
ysis shows that all helicase mutants except for Mut V had a
defect in virion packaging. Consistently, we found that only
Mut V did not lose anti-HIV-1 activity (Fig. 5A). Motif I has a
GXXXXGKT/S consensus and binds to phosphates; and motif
II has a DEXX consensus and binds to magnesium. These two
motifs catalyze the hydrolysis of purine nucleoside triphos-
phate, providing energy for helicase activity. The other five
FIGURE 7. A and B, anti-HIV-1 activity ofMOV10 deletionmutants, as determined in Fig. 5A. Protein expression in cells and virions in Bwas determined as in Fig.
4.
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motifs are more diverse, and they could contribute to RNA or
DNA binding (32). It is unclear why motif V is not required for
MOV10 virion packaging. It is possible that we did not com-
pletely inactivate this helicase motif when this mutant was cre-
ated. Nonetheless, we conclude that the helicase domain serve
as another packaging signal for MOV10. It is known that heli-
case motifs have high affinity to RNAs.We speculate that RNA
binding may change protein conformation and facilitate
MOV10 encapsidation by the virus.
In addition to these packaging signals, we have identified
several other critical residues that are required for MOV10
anti-HIV-1 activity. We have found that nearly all MOV10 res-
idues (AA 99–949) are required for its antiviral activity. In this
region, we found that in addition to those packaging signals,
both the N-terminal region and the C-terminal region are crit-
ical for MOV10 anti-HIV-1 activity. Although individually
mutating histidine and cysteine residues in the CH domain did
not disruptMOV10 anti-HIV-1 activity, simultaneouslymutat-
ing residues Cys-188, Cys-195, His-199, His-201, and His-202
seriously compromised MOV10 activity (Fig. 6C). We also
found that the C-terminal residues Cys-947, Pro-948, and Phe-
949 are also critical for MOV10 antiviral activity (Fig. 7B).
These results indicate that in addition to Gag binding and
virion packaging, there is another critical step(s) that controls
MOV10 antiviral activity. Further identification of this step(s)
will lead to a more comprehensive understanding of MOV10
antiviral activity.
In summary, we have identified two determinants for
MOV10 packaging and eight other residues for MOV10 anti-
HIV-1 activity. These results provide a molecular basis for
understanding MOV10 antiretroviral mechanism.
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Abudu_Fig. S1
Fig. S1. Amino acid sequence alignment of human UPF1 protein residues 116-913 and MOV10 residues 122-968.
It was preformed at Discovery Studio Client 2.5. The similar or identical residuals are showed in light blue or dark blue 
color respectively. The dash sign means deletion, and the sequence numbers are the actual residue numbers in their structures, 
which are different from their whole protein numbering.  
